Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs. In particular, Aptorum Group is currently developing therapeutics in the areas of orphan oncology, infectious diseases, metabolic diseases and woman’s health.
Targeted development milestones for some of the key programs include the followings:
SACT-1 (Neuroblastoma & Other Solid Tumours): a repurposed drug program with prior human safety and toxicity data available, targeted for IND submission under the US FDA 505b(2) pathway in 2020 to initiate Ph1b/2a clinical studies in 2021;
ALS-4 (Next generation anti-infective for Staphylococcus aureus including MRSA): a new chemical entity (NCE) small molecule drug currently in completion of its IND enabling studies, targeted for regulatory submission in 2020 to initiate a Ph1 clinical study in Canada;
CLS-1 (Microbiome-based approach for Obesity): currently in lead optimization stage of development, targeted for IND enabling studies to commence in 2021;
NLS-2 NativusWell® (dietary supplement for woman's health including menopause and osteoporosis): supplement containing naturally occurring plant based bioactive ingredient currently under registrations in UK, Europe and Asia, targeted for commercialization in H2 2020.
Please watch our company presentation at bioinvestorforum20.hubb.me/schedule-builder/sessions/717681
Below are the links to our general corporate presentations:
Corporate ppt: https://ir.aptorumgroup.com/static-files/ca36cc65-6f23-4105-895e-f5f234ecca1e
One pager: https://ir.aptorumgroup.com/static-files/d768100e-d136-47c0-a3ae-fb9c4f8a4260
Fact sheet: http://ir.aptorumgroup.com/static-files/e4838abb-ac1e-4241-adad-3fa5f0c89423
Targeted development milestones for some of the key programs include the followings:
SACT-1 (Neuroblastoma & Other Solid Tumours): a repurposed drug program with prior human safety and toxicity data available, targeted for IND submission under the US FDA 505b(2) pathway in 2020 to initiate Ph1b/2a clinical studies in 2021;
ALS-4 (Next generation anti-infective for Staphylococcus aureus including MRSA): a new chemical entity (NCE) small molecule drug currently in completion of its IND enabling studies, targeted for regulatory submission in 2020 to initiate a Ph1 clinical study in Canada;
CLS-1 (Microbiome-based approach for Obesity): currently in lead optimization stage of development, targeted for IND enabling studies to commence in 2021;
NLS-2 NativusWell® (dietary supplement for woman's health including menopause and osteoporosis): supplement containing naturally occurring plant based bioactive ingredient currently under registrations in UK, Europe and Asia, targeted for commercialization in H2 2020.
Please watch our company presentation at bioinvestorforum20.hubb.me/schedule-builder/sessions/717681
Below are the links to our general corporate presentations:
Corporate ppt: https://ir.aptorumgroup.com/static-files/ca36cc65-6f23-4105-895e-f5f234ecca1e
One pager: https://ir.aptorumgroup.com/static-files/d768100e-d136-47c0-a3ae-fb9c4f8a4260
Fact sheet: http://ir.aptorumgroup.com/static-files/e4838abb-ac1e-4241-adad-3fa5f0c89423
Ticker:
APM
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2010
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
SACT-1, ALS-4
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
